Cargando…
P05 In vivo efficacy of VRP-034 in lung and thigh infection models
BACKGROUND: Polymyxin B-induced kidney injury is an important clinical concern that undermines patient care. This injury occurs in 30%–60% of patients receiving systemic polymyxin B (PMB). VRP-034, a novel PMB formulation, has previously shown a promising safety profile as compared with marketed PMB...
Autores principales: | Vishwakarma, Kamlesh Kumar, Payasi, Anurag, Kumar, Shailesh, Sharma, Arun, Chaudhary, Saransh, Aggarwal, Anmol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040012/ http://dx.doi.org/10.1093/jacamr/dlac004.004 |
Ejemplares similares
-
P06 Pharmacokinetics and renal accumulation of VRP-034
por: Vishwakarma, Kamlesh Kumar, et al.
Publicado: (2022) -
P07 Toxicokinetic profile of VRP-034
por: Murkunde, Yogeshkumar Vishnupant, et al.
Publicado: (2022) -
Polymyxin B-Induced Kidney Injury Assessment of a Novel Formulation of Polymyxin B (VRP-034) in Rats
por: Roy, Dilip, et al.
Publicado: (2021) -
Ceftriaxone+Sulbactam+Disodium EDTA Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial
por: Mir, Mohd Amin, et al.
Publicado: (2019) -
P034. Technostress and primary headache: psychosocial risk
por: Pucci, Ennio, et al.
Publicado: (2015)